Tilray Brands Inc

Tilray Brands Inc(TLRY)股票分析

$4.590

+0.020 (+0.44%)收盤時

Loading chart…
High
4.655
Open
4.550
VWAP
4.58
Vol
3.38M
Mkt Cap
1.43B
Low
4.490
Amount
15.46M
EV/EBITDA, TTM
-1.49

Tilray Brands, Inc. is a lifestyle consumer products company, which focuses on providing research-backed medical cannabis products to physicians, pharmacies, and patients around the world. The Company operates in four segments, which include cannabis operations, which encompasses the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. Beverage operations, which encompasses the production, marketing, and sale of beverage products. Distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers, and Wellness products, which encompasses wellness and better-for-you foods and beverages. It offers a portfolio of brands and products across medical and adult-use cannabis, craft beer, spirits, beverages, and hemp foods. It also owns digital healthcare and patient engagement platform, focused on medical cannabis education, physician consultations, and patient support services.

AI analysis of Tilray Brands Inc (TLRY)

hold

Tilray Brands Inc is currently not a strong buy due to ongoing financial challenges despite some positive revenue growth. The current price is $4.59, and the company reported a net loss of $49.6 million in its latest earnings report. While the gross margin has improved to 29.93%, the forward P/E ratio is extremely high at 1000, indicating that the stock may be overvalued given its current financial performance. The main risk is the substantial net loss, which raises concerns about the company's profitability moving forward.

Analyst Ratings (3)

+108.50% upside
Buy
3 Buy
0 Hold
0 Sell
Current: 4.59
最低
8.50
平均
9.57
最高
10.00

TD Cowen

2026-07-14

目標價

$5

Buy

Canaccord

2026-04-02

目標價

$13

Hold

Roth Capital

2026-04-01

目標價

$10

Buy

Alliance Global

2026-04-01

目標價

$7

Neutral

TD Cowen

2026-03-30

目標價

$7

Buy

估值指標

The current forward P/E ratio for Tilray Brands Inc (TLRY) is 1000.00, compared to its 5-year average forward P/E of 126.48.

Forward P/E

Strongly Overvalued
5Y Average P/E
126.48
Current P/E
1000.00
高估
500.02
低估
-247.06

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
26.60
Current EV/EBITDA
-1.49
高估
49.62
低估
3.58

Forward P/S

Fair
5Y Average P/S
2.32
Current P/S
0.54
高估
4.20
低估
0.44

Alphio AI Price Scenarios for TLRY

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TLRY

$0.55

情境價格

B

Base

Base · 50%TLRY

$0.49

情境價格

B

Bear

Bear · 25%TLRY

$0.44

情境價格

事件時間軸

2026-08-20 (ET)

07:30:00

Tilray Expands Global Cannabis Cultivation Capacity to 275 Metric Tons

2026-07-28 (ET)

17:00:00

Tilray Reports Q4 Revenue of $281.7M

17:00:00

Sees FY27 Adjusted EBITDA of $68M-$75M

2026-07-07 (ET)

09:00:00

Starfighters Space Borrow Rate Increases to 116.23%

2026-06-29 (ET)

17:30:00

Tilray Acquires HelloMD to Expand Medical Cannabis Business

資訊

TLRY FAQ — answered by Alphio AI

Tilray Brands, Inc. is a lifestyle consumer products company, which focuses on providing research-backed medical cannabis products to physicians, pharmacies, and patients around the world. The Company operates in four segments, which include cannabis operations, which encompasses the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. Beverage operations, which encompasses the production, marketing, and sale of beverage products. Distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers, and Wellness products, which encompasses wellness and better-for-you foods and beverages. It offers a portfolio of brands and products across medical and adult-use cannabis, craft beer, spirits, beverages, and hemp foods. It also owns digital healthcare and patient engagement platform, focused on medical cannabis education, physician consultations, and patient support services. It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Tilray Brands Inc is currently not a strong buy due to ongoing financial challenges despite some positive revenue growth. The current price is $4.59, and the company reported a net loss of $49.6 million in its latest earnings report. While the gross margin has improved to 29.93%, the forward P/E ratio is extremely high at 1000, indicating that the stock may be overvalued given its current financial performance. The main risk is the substantial net loss, which raises concerns about the company's profitability moving forward.

3 analysts cover TLRY: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.57.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始